Founded in 2014, NOTA Laboratories is focused on developing NO delivery platform technologies that have broad applicability in advancing the treatment for many debilitating and potentially life-threatening conditions and diseases, including Sars CoV-2 (COVID-19), the seasonal flu, the common cold, systemic inflammatory response syndrome (SIRS), chronic rhinosinusitis (CRS), COPD, and catheter related bloodstream infection (CRBSI).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/16/22 | undisclosed | Second Round |
Pegasus Tech Ventures | undisclosed |
